<?xml version="1.0" encoding="UTF-8"?>
<collection>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd http://dublincore.org/schemas/xmls/qdc/dcterms.xsd"><dc:language>eng</dc:language><dc:creator>Zhao, Jingyi</dc:creator><dc:creator>DiGiacomo, Vincent</dc:creator><dc:creator>Garcia-Marcos, Mikel</dc:creator><dc:creator>Ferreras-Gutierrez, Mariola</dc:creator><dc:creator>Dastjerdi, Shiva</dc:creator><dc:creator>Ibanez de Opakua, Alain</dc:creator><dc:creator>Park, Jong-Chan</dc:creator><dc:creator>Luebbers, Alex</dc:creator><dc:creator>Chen, Qingyan</dc:creator><dc:creator>Beeler, Aaron</dc:creator><dc:creator>Blanco, Francisco J</dc:creator><dc:title>Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer.</dc:title><dc:subject>info:eu-repo/classification/ddc/500</dc:subject><dc:subject>Vesicular Transport Proteins: metabolism</dc:subject><dc:subject>Microfilament Proteins: metabolism</dc:subject><dc:subject>Signal Transduction</dc:subject><dc:subject>Receptors, G-Protein-Coupled: metabolism</dc:subject><dc:subject>Heterotrimeric GTP-Binding Proteins: metabolism</dc:subject><dc:subject>Neoplasms: metabolism</dc:subject><dc:subject>G protein</dc:subject><dc:subject>GPCR</dc:subject><dc:subject>cancer</dc:subject><dc:subject>drug discovery</dc:subject><dc:subject>Vesicular Transport Proteins</dc:subject><dc:subject>Microfilament Proteins</dc:subject><dc:subject>Receptors, G-Protein-Coupled</dc:subject><dc:subject>Heterotrimeric GTP-Binding Proteins</dc:subject><dc:description>Activation of heterotrimeric G-proteins (Gαβγ) by G-protein-coupled receptors (GPCRs) is a quintessential mechanism of cell signaling widely targeted by clinically approved drugs. However, it has become evident that heterotrimeric G-proteins can also be activated via GPCR-independent mechanisms that remain untapped as pharmacological targets. GIV/Girdin has emerged as a prototypical non-GPCR activator of G proteins that promotes cancer metastasis. Here, we introduce IGGi-11, a first-in-class small-molecule inhibitor of noncanonical activation of heterotrimeric G-protein signaling. IGGi-11 binding to G-protein α-subunits (Gαi) specifically disrupted their engagement with GIV/Girdin, thereby blocking noncanonical G-protein signaling in tumor cells and inhibiting proinvasive traits of metastatic cancer cells. In contrast, IGGi-11 did not interfere with canonical G-protein signaling mechanisms triggered by GPCRs. By revealing that small molecules can selectively disable noncanonical mechanisms of G-protein activation dysregulated in disease, these findings warrant the exploration of therapeutic modalities in G-protein signaling that go beyond targeting GPCRs.</dc:description><dc:source>Proceedings of the National Academy of Sciences of the United States of America 120(18), e2213140120 (2023). doi:10.1073/pnas.2213140120</dc:source><dc:type>info:eu-repo/semantics/article</dc:type><dc:type>info:eu-repo/semantics/publishedVersion</dc:type><dc:publisher>National Acad. of Sciences</dc:publisher><dc:date>2023</dc:date><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:coverage>DE</dc:coverage><dc:identifier>https://pub.dzne.de/record/257779</dc:identifier><dc:identifier>https://pub.dzne.de/search?p=id:%22DZNE-2023-00494%22</dc:identifier><dc:audience>Researchers</dc:audience><dc:relation>info:eu-repo/semantics/altIdentifier/issn/0027-8424</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1073/pnas.2213140120</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/pmid/pmid:37098067</dc:relation><dc:relation>info:eu-repo/semantics/altIdentifier/issn/1091-6490</dc:relation></oai_dc:dc>

</collection>